BACKGROUND: Statin therapy is recommended for reducing atherosclerotic cardiovascular disease (ASCVD) risk. Significant risk can remain because of insufficient clinical response or statin intolerance. Proprotein convertase subtilisin/kexin type-9 (PCSK9) therapy lowers low-density lipoprotein cholesterol and has recently been shown to lower ASCVD events.
Introduction
Statins have been approved in the United States since 1987 and are widely used in both secondary and primary prevention of atherosclerotic cardiovascular disease (ASCVD) because of their proven benefits. 1 However, statin therapy has some important limitations. First, even with high-intensity statin treatment, some patients can fail to attain desired low-density lipoprotein cholesterol (LDL-C) reductions, and therefore remain at high risk of a cardiovascular (CV) event. 2 Patients with untreated familial hypercholesterolemia (FH) have markedly elevated LDL-C levels, 3 and in this group, a large proportion fail to attain LDL-C goals despite therapy with maximally tolerated statins plus ezetimibe. 4 Second, some patients do not tolerate statins and are considered ''statin intolerant,'' with statin-associated muscle symptoms being the most common. 5 The incidence of statin intolerance (SI) has been difficult to estimate because of varying clinical trial designs, lack of ability to easily identify SI in postmarket assessment, and differing agents being used. 5 An Internet survey conducted by the National Lipid Association (NLA) of 10,138 current and former statin users (Understanding Statin Use in America and Gaps in Patient Education) found that 60% of former and 25% of current statin users reported muscle symptoms while taking a statin. 6 Therefore, it is clear that statins may not be sufficient for LDL-C control in some patients, and other options are needed to ensure that more high-risk patients (ASCVD/FH) with elevated LDL-C are able to achieve treatment goals.
Relatively, recent research in the field of clinical lipidology has led to the development of inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9). 7 PCSK9 is a key regulator of hepatic LDL receptor (LDL-R) activity. PCSK9 binds to the LDL-R expressed on the cell surface of hepatocytes, where it prevents recycling of the LDL-R and therefore promotes its degradation. 8 The result of PSCK9 inhibition is to enable more hepatic LDL-R to bind and sequester LDL-C, and thereby reduce circulating LDL-C levels, as well as levels of other potentially atherogenic lipoproteins such as very low-density lipoproteins and lipoprotein(a). 8 At present, 2 injectable fully human monoclonal antibody PCSK9 inhibitors have been approved by the Food and Drug Administration-alirocumab (Praluent; Sanofi/ Regeneron Pharmaceuticals) 9 and evolocumab (Repatha; Amgen). 10 Both of these agents are indicated as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous FH or clinical ASCVD, who require additional lowering of LDL-C.
9,10 Recently, results from the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk (FOURIER) trial demonstrated that addition of evolocumab to statin therapy significantly reduced CV event rates by 15% to 20% in patients with ASCVD.
11
Given that PCSK9 inhibitors are relatively costly monoclonal antibodies, access to the approval for the use of these drugs is often limited, which can impede optimal CV risk management. Therefore, it is important to understand what the barriers to PCSK9 inhibitor prescription approval are such that healthcare systems and processes can be structured to deliver appropriately targeted, high-quality care to patients who will benefit from additional lipid-lowering therapy with these agents.
The NLA routinely publishes recommendations and statements for healthcare professionals, payers, and policy makers with the aim of optimizing the treatment of patients with dyslipidemias. For PCSK9 inhibitors, an online survey of NLA members, and other invited participants with experience in treating patients with lipid disorders, was conducted to gather information on prescribing patterns and barriers in PCSK9 inhibitor use. The major findings of this survey are reported here.
Methods
An online survey, developed by the NLA and administered by Professional Research Consultants Inc (Omaha, NE, USA), was conducted between August 26, 2016 and October 14, 2016 (open for 6 weeks). Invitees were NLA members and selected external healthcare professionals with interest and experience in caring for patients with dyslipidemias. Reminders to complete were sent over the 6-week period of the survey and at the American Society of Preventive Cardiology Annual Meeting, September 2016. The survey was also advertised by the NLA via e-mail, web advertisements on the NLA and media partners' Web sites, postcards to NLA members, social media, and responder referrals.
The survey included 170 questions designed to query the demographic and job function of the respondents, the general profile of the patients under their care (with particular reference to those at high risk of ASCVD), statin use, and treatment decisions regarding PCSK9 inhibitors. Questions were provided by an experienced group of lipid experts. The NLA was solely responsible for the creation of the questions and content of the survey. The questions were constructed as multiple-choice options along with free-text fields for completion. Most questions were multiple choice with no more than 5 answer options. Open questions with ''other'' options and free-text responses were categorized and coded according to recommendations from NLA experts using normal clinical vocabulary.
The survey was designed to take approximately 20 minutes to complete, and no payment was provided to respondents. The survey was conducted using a standard web interface operable via web browser software. Data were collected by Professional Research Consultants Inc and processed according to an analysis plan that was adapted by the NLA according to responses to key questions. Data are presented in a descriptive format.
No institutional review board approval was required for this survey.
Results

Participants
The survey included 434 respondents. Of these 264 (61%) were physicians. More than three-quarters of the self-identified lipid specialists stated that they were certified by either the American Board of Clinical Lipidology or the Accreditation Council for Clinical Lipidology. More than two-thirds (69.7%) stated that they had access to staff to assist them with the drug approval process (Table 1) . Eighty-five percent of respondents were responsible for writing prescriptions.
Statin use and provider practice patterns
Most respondents (84.3%) stated that, in line with recommendations from the NLA, 12 they prescribe lipidlowering medication to achieve a specific LDL-C target, and the remainder (15.7%) treated to a specific high-dose statin. To achieve these targets, 34.6% of respondents had more than 75% of their high-risk patients on highintensity statin therapy (20-40 mg rosuvastatin or 40-80 mg atorvastatin). Twenty-seven percent had between 51% and 75% of high-risk patients on high doses, 22.4% had between 26% and 50% of their high-risk patients on high doses, and 15% had fewer than one-quarter of their high-risk patients on high-intensity stain therapy. These data indicate that although most physicians (61.9%) are striving to maintain high-intensity statin therapy, there remains a substantial proportion of patients at high ASCVD risk who are unable to tolerate high-intensity statin therapy. The reasons given for not using high-intensity statin therapy in certain high-risk patients were varied (Fig. 1) . Among 419 respondents answering the question, 413 (98.5%) stated that high-intensity statin therapy was not used because of side effects or intolerance (294 [70% gave this as their first answer]). Lack of adherence (n 5 271, 64%) and patients preferring other treatments (n 5 229 55%) were the other common reasons cited ( Fig. 1) .
In the survey, 60.9% of respondents said that up to onequarter of their high-risk patients have an intolerance to statins that prevents their patients from reaching their LDL-C goals. Among the adverse events experienced, almost all the respondents (96.6%) stated that muscle pain and/or weakness was the most common complaint. Similarly, 70.5% of respondents estimated that up to 25% of their patients do not adhere to statin prescriptions or prefer not to use the drugs. In most cases (83.3% of Figure 1 Reasons for not using high-intensity statin therapy in certain high ASCVD-risk patients. Values represent the number of respondents choosing each category; reasons for not applying high-intensity statin therapy in high ASCVD-risk patients were recorded according to whether they were the first, second, or third response from the survey respondents (n). Total values are given on the ends of the bars. ASCVD, atherosclerotic cardiovascular disease. Figure 2 Actions taken for lack of efficacy on maximum tolerated statin dose (A) and actions taken for lack of efficacy because of statin side effects (B). Values represent the number of respondents choosing each category; nonresponse to statins was defined as able to tolerate a high-intensity statin but unable to achieve their target LDL-C goal or an LDL-C reduction $50%; *once ''take no further action'' was been selected, respondents were not asked about additional actions taken. LDL, low-density lipoprotein cholesterol. respondents), these patients first received counseling to explain, for example, the importance of taking their medication and the risks associated with failure to lower LDL-C levels. PCSK9 inhibitors were chiefly tried as a fourth option after counseling, statin change, and adjunctive therapy in patients who do not adhere or prefer not to take statins (56.4% of respondents).
Attempts to maintain statin therapy in these patients was evidenced by the fact that more than 75% of respondents routinely try 3 or more statin medications before considering a high-risk patient to be statin intolerant.
Use of adjunctive nonstatin therapies
For high-risk patients who are unable to achieve their LDL-C target on a maximally tolerated statin dose, most respondents (85.4%) would then add nonstatin adjunctive therapy, with ezetimibe as the leading initial choice. After that, 71.3% would try a PCSK9 inhibitor as second choice. More than one-quarter of respondents (27.3%) would take no further action on statin failure ( Fig. 2A) . For those patients in whom statin-associated side effects were preventing them from reaching LDL-C goals, most respondents (63.0%) would first stop the statin to see if the patient's symptoms disappear. If the symptoms disappeared, the next course of action was for providers to change either the statin or the statin dose, before trying a PCSK9 inhibitor (71.4% opted for a PCSK9 inhibitor as their third line of action; Fig. 2B ).
Provider variability in PCSK9 inhibitor prescribing rates
Most of the respondents have attempted to get approval for a PCSK9 inhibitor. However, 1 in 6 (16.9%) have never attempted to prescribe a PCSK9 inhibitor for any of their patients with ASCVD, and 1 in 7 (14.8%) have never attempted to prescribe for their patients with FH. Among those who have prescribed a PCSK9 inhibitor for their patients with ASCVD, most (57.6%) have prescribed ,10% of their ASCVD patients. Attempts to prescribe a PCSK9 inhibitor for a patient with FH was greater than for a patient with ASCVD; however, 37.5% of respondents have attempted to prescribe a PCSK9 inhibitor in more than half of their FH patients.
It was observed that most respondents reported that many of their high-risk patients are not able to reach their LDL-C goals and that 71.4% would prescribe a PCSK9 inhibitor in their high-risk patients who are on a maximally tolerated statin regimen and not at their clinical goals. However, fewer have actually attempted to seek approval for a PCSK9 inhibitor.
Among the small number of respondents who had never attempted to prescribe a PCSK9 inhibitor, the chief reasons given for not prescribing the drugs for FH were the patient being at goal and the cost of the drugs (10 of 46 available responses [21.7%] for each reason). For ASCVD, 18 of 59 respondents (30.5%) stated that cost to the patient was the chief barrier preventing them from seeking permission for a PCSK9 inhibitor. Seven respondents suggested that excessive paperwork was the leading reason for not seeking a PCSK9 inhibitor for ASCVD.
Differences in perceived LDL thresholds between providers and payers
Another important barrier is that payers may have higher LDL-C thresholds for approval than is the case for providers. Figure 3 shows commonly applied threshold LDL-C values at which physicians will prescribe a Figure 3 Threshold LDL-C values to trigger PCSK9 inhibitor prescriptions and respondents' experienced approval levels for (A) ASCVD and (B) FH. Values represent the number of respondents choosing each category; data from respondents who believe there is a threshold LDL-C value on optimal therapy for which a payer would approve a PCSK9 inhibitor; payer values are prescriber perceptions. ASCVD, atherosclerotic cardiovascular disease; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; PCSK9, Proprotein convertase subtilisin/kexin type-9.
PCSK9 inhibitor vs the level at which physicians have experienced payers approving. The graph shows the percentage of respondents who cited each of the given LDL-C ranges as their most frequently encountered threshold. For both FH and ASCVD patients, the respondents indicated that they use lower thresholds for initiating PCSK9 inhibitor requests than payers.
PCSK9 inhibitor denial rates and reasons for denial
For those who attempted to obtain approval to prescribe a PCSK9 inhibitor, denial rates of more than 75% were reported by 33.5% of respondents attempting to treat ASCVD patients and 25.2% of patients attempting to treat an FH patient. Despite multiple appeals, 64% and 57% of respondents with ASCVD and FH patients, respectively, were unable to get three-quarters of their prescriptions approved (Fig. 4) . The reasons given for denial were mainly because of documentation issues. For FH, 148 of 267 respondents (55.4%) stated that inadequate documentation of FH was among the most common reasons for denial of a PCSK9 inhibitor (Fig. 5B) . Additional medical documentation and a lack of current laboratory values combined were cited by 154 respondents (57.6%) as reasons for denial. For ASCVD, 72% (228/316) of providers reported that it was not on the insurance formulary (as their top first, second, and third choice). Documentation-related problems were evident in 311 responses (98.4%; Fig. 5A ). Lack of documentation as to why the patient is not on a high-intensity statin, or why a patient is on a maximally tolerated statin dose, was the third most common reason for a denial in ASCVD patients and second most common reason for FH patients.
Types of assistance that providers request to improve PCSK9 inhibitor approval rates Figure 6 shows what type of assistance respondents would like to receive to enable successful PCSK9 inhibitor applications. The most common request was for improvements to the overall application and reimbursement process (21% of respondents), and documentation appears again as an important factor (12.6% of respondents cited ''documentation,'' and a further 8.6% said ''paperwork'').
The survey found that practice staff is completing documentation for 52.0% of applications, and physicians for only 28.9%. Almost one-quarter of respondents (24.1%) said that they took more than 2 h/wk to complete. Just over one-quarter of respondents (27.8%) said that the applications took 30 to 59 minutes; 26.6% said 1 to 2 hours. For 21.5% of these staff, PCSK9 inhibitor prescription applications consumed ,30 min/wk. Importantly, among those taking more than 2 hours to complete the documentation, 10.3% of respondents were physicians, and 30.8% were other practice staff. For those taking #30 minutes, 35.9% were physicians, and 14.5% were practice staff.
Respondents were asked to identify the important keys to successful navigation of the PCSK9 inhibitor approval process. The results are shown in Figure 7 and highlight that accurate and current documentations are critical. 
Discussion
The survey was completed by healthcare providers, mainly physicians and others who are experienced in treating patients with lipid disorders. The principal findings are that those treating ASCVD and FH patients are using statins and nonstatin therapies consistent with recommendations from the NLA 12, 13 and in accordance with the principles of the recent consensus update on nonstatin therapies from the American College of Cardiology/American Heart Association (ACC/AHA). 14 The findings from our study also confirm results from other studies that in real-world practice, many high-risk patients are not able to tolerate high-intensity statins and fail to achieve their LDL-C goals. 15, 16 For these patients, our survey results demonstrate that there is a desire to use PCSK9 inhibitors after adjuvant therapy has been added. Data suggest that respondents consider prescribing a PCSK9 inhibitor, but there is reluctance in actually prescribing one, possibly because of perceived unattainable thresholds applied by payers. The data clearly show that there are barriers to PSCK9 inhibitor prescription approval, but these can often be surmounted with adequate documentation and persistence.
A strength of this survey is the number of respondents and their varied roles. The intent was to include experienced healthcare providers who are involved in the process of gaining approval for use of PCSK9 inhibitors, and many of them were not necessarily physicians. The survey included 434 respondents, and by design, most were members of the NLA. Among the sample, most respondents were lipid specialists or cardiologists, many of whom were certified as such. These are the types of individuals that are needed to generate high-quality and actionable data on practice patterns of statin and PCSK9 inhibitor use.
Approximately 80% of respondents said that they treated to an LDL-C goal rather than a given dose of statins. This is in line with the current NLA recommendations, 14 which suggest that LDL-C levels should be lowered to specific goals, depending on ASCVD risk level (,70 mg/dL for very high risk or ,100 mg/dL for others), and by at least 50% in those unable to reach these levels. 14 The survey did not collect data on goal attainment, but expectations have been that the introduction of the updated recommendations from both the NLA and ACC/AHA will have a positive impact on achieving LDL-C goals in clinical practice. 17 The large proportion of respondents stating that they treat to LDL-C goals may reflect the fact that the large proportion of respondents were members of the NLA, which has published recommendations on LDL-C (and non-HDL-C) goals. 12, 13 Further encouraging are the data gathered on physician persistence with statins. When faced with a patient who fails to achieve LDL-C targets on their maximally tolerated statin dose, the vast majority of respondents stated that they would add adjunctive therapy, which would presumably be ezetimibe in most instances. It was only at the next decision point where physicians would consider PCSK9 inhibitors. This progression through statins, adjunctive therapies, and PCSK9 inhibitors is entirely commensurate with the need to keep patients on high-dose statins for as long as possible and use other therapies after statin options have been exhausted. This practice is in line with NLA recommendations and the recently published ACC consensus statement. [12] [13] [14] For patients who have tolerability issues with statins, the same treatment approach was evident in the survey, with the exception of adding the initial step of stopping the statin to determine adverse event causality. Cessation of statin therapy while adverse events are reassessed is good clinical practice. In both situations (patients failing to reach LDL-C targets on high-intensity statin therapy, and patients who do not tolerate statins), most of the respondents would do something positive about the situation-first adding an adjunctive therapy and then trying to add a PCSK9 inhibitor. Overall, the picture of the survey respondents is a group of well-informed healthcare professionals who follow ACC/AHA and/or NLA recommendations and have a proactive attitude toward achieving the best outcomes possible for their patients.
The main reason given for high-risk patients not receiving high-intensity statin therapy was adverse events, chiefly myalgia. The survey data highlighted some issues of patient preference to avoid statins as well as patient noncompliance with prescribed statins, but these responses may also have their genesis in actual (or fear of) statininduced myalgia and other side effects. The NLA has recently published advice for clinicians who need to counsel patients on SI and has made research suggestions for trials that would enable full characterization of the condition. 5 A key issue with PCSK9 inhibitor use comes when healthcare teams apply for approval. The survey has identified 2 types of modifiable barriers beyond the drug not being on formulary. The first of these lies with payers who may apply LDL-C thresholds to enable PCSK9 inhibitor use that are higher than the thresholds preferred by many healthcare teams. Therefore, some clinicians who may wish to use a PCSK9 inhibitor in a high-risk patient may be denied access because the LDL-C value in the patient may be lower than the threshold for approval set by the payer. This barrier can only be addressed with additional evidence demonstrating to payers that lower LDL thresholds are clinically indicated and lead to improved outcomes. The same solution applies to those situations where the formularies do not include PCSK9 inhibitors. Additional data, on PCSK9 inhibitors, such as those from the recent FOURIER trial, 11 are likely to alter the position taken by payers.
The second principal barrier was found to be documentation. In almost all instances, respondents cited reasons for PCSK9 inhibitor denial as being associated with deficient documentation of one kind or another. In many cases, once adequate documentation is provided, the reapplication eventually results in approval. The need for adequate documentation is a straightforward problem and should be relatively easy to overcome. A checklist of all the required documents to support an approval, including medical history, clinical and genetic confirmation (in the case of FH), history of statin use, current statin dose and, if the patient is not on a high intensity statin, the reason why, and a full set of laboratory values, including LDL-C, ,30 days before the application is recommended. In our survey, in just over one-half of respondents, the documentation needed to prescribe a PCSK9 inhibitor was compiled by the physician's office staff. Therefore, it is important that the responsible staff also be trained in compiling this documentation.
The survey data include some reasons for optimism. Approximately, 96% of respondents took some further action after a denial and persisted in their attempts for seeking approval. After initial refusal, many respondents were eventually successful in obtaining approval for a PCSK9 inhibitor. In Table 2 , see a proposed checklist to assist healthcare teams that are seeking approval to prescribe a PCSK9 inhibitor.
The survey conducted has some limitations inherent in its design and broad scope. In a survey of this type, it is not possible to cover every eventuality. There is a possibility that the multiple-choice response options did not include some lesser-known modes of therapy or motivations to prescribe. This was minimized by categorizing individual free-text responses. For LDL-C thresholds applied by payers, individual assessment of LDL-C values by respondent was not done. In addition, at the time of the survey, data on the safety and efficacy of PCSK9 inhibitors, were building rapidly; however, outcome results were not yet available. Therefore, for some payers, it may not have been a matter of LDL-C thresholds, but a lack of outcome data resulted in prescription denial. This situation may change with the recent publication of the FOURIER trial, which presented CVD outcomes data for PCSK9 inhibitors. 11 As a final note on limitations, the nature of adjunctive therapy added to statins was not identified.
In summary, healthcare teams are trying to follow guidelines for treating patients at high-risk of ASCVD events, but they frequently encounter barriers to approval of PCSK9 inhibitor prescription reimbursement. Healthcare teams are motivated to overcome these barriers to continue to provide high-quality care to patients who cannot achieve LDL-C targets with statins alone. Training of those involved in the application process and good documentation have the potential to improve individualized care of high-risk patients. Persistence with failed applications is important and can be summarized by this quote from Thomas Edison: ''Our greatest weakness lies in giving up. The most certain way to succeed is always to try just one more time.''
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